Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bishop

Showing results (941-950 of 1,042) with videos related to

Pageof 105
Sort By:
The Lancet. Oncology|September 13, 2021
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyStephen J Schuster, Constantine S Tam, Peter Borchmann, et al.
Blood|April 10, 2008
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remissionDavid I Marks, Waleska S Pérez, Wensheng He, et al.
The New England Journal of Medicine|November 27, 2024
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Karamjeet S Sandhu, Eleni Tholouli, et al.
Blood Advances|May 5, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphomaJoseph P McGuirk, Armin Ghobadi, Carlos R Bachier, et al.
American Journal of Human Genetics|June 24, 2020
Genome-wide Enrichment of De Novo Coding Mutations in Orofacial Cleft TriosMadison R Bishop, Kimberly K Diaz Perez, Miranda Sun, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Clinical and Translational Science|September 25, 2021
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapySony Tuteja, Ramzi G Salloum, Amanda L Elchynski, et al.
Implementation Science Communications|May 15, 2022
Best-worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapyRamzi G Salloum, Jeffrey R Bishop, Amanda L Elchynski, et al.
Lancet (London, England)|June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 22, 2019
Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribingLarisa H Cavallari, Sara L Van Driest, Cynthia A Prows, et al.
Pageof 105

Showing results (941-950 of 1,042) with videos related to

Sort By:
Pageof 105
The Lancet. Oncology|September 13, 2021
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyStephen J Schuster, Constantine S Tam, Peter Borchmann, et al.
Blood|April 10, 2008
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remissionDavid I Marks, Waleska S Pérez, Wensheng He, et al.
The New England Journal of Medicine|November 27, 2024
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Karamjeet S Sandhu, Eleni Tholouli, et al.
Blood Advances|May 5, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphomaJoseph P McGuirk, Armin Ghobadi, Carlos R Bachier, et al.
American Journal of Human Genetics|June 24, 2020
Genome-wide Enrichment of De Novo Coding Mutations in Orofacial Cleft TriosMadison R Bishop, Kimberly K Diaz Perez, Miranda Sun, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Clinical and Translational Science|September 25, 2021
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapySony Tuteja, Ramzi G Salloum, Amanda L Elchynski, et al.
Implementation Science Communications|May 15, 2022
Best-worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapyRamzi G Salloum, Jeffrey R Bishop, Amanda L Elchynski, et al.
Lancet (London, England)|June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 22, 2019
Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribingLarisa H Cavallari, Sara L Van Driest, Cynthia A Prows, et al.
Pageof 105